Sagimet Biosciences (SGMT) Enterprise Value (2022 - 2026)

Sagimet Biosciences' Enterprise Value history runs 5 years deep, the most recent figure standing at -$104.5 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 27.69% year-over-year to -$104.5 million; the TTM figure through Mar 2026 stood at -$104.5 million (up 27.69% YoY), while the FY2025 annual figure was -$113.1 million, up 25.21% from the prior year.
• Enterprise Value was -$104.5 million for Q1 2026 at Sagimet Biosciences, up from -$113.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$18.5 million in Q2 2023 to a low of -$193.7 million in Q1 2024.
• Historically, Enterprise Value has averaged -$116.6 million across 5 years, with a median of -$116.7 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Enterprise Value sank 798.92% in 2024, then gained 27.69% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$32.3 million in 2022, then tumbled by 193.39% to -$94.9 million in 2023, then sank by 59.38% to -$151.2 million in 2024, then advanced by 25.21% to -$113.1 million in 2025, then rose by 7.59% to -$104.5 million in 2026.
• The last three Enterprise Value figures came in at -$104.5 million (Q1 2026), -$113.1 million (Q4 2025), and -$116.7 million (Q3 2025), per Business Quant data.